

Unrelated Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|---|--|--|
| Number of patients | 47323 | 19111 | 12053 |
| Source of data | | | |
| CRF | 24443 (52) | 7079 (37) | 5666 (47) |
| TED | 22880 (48) | 12032 (63) | 6387 (53) |
| Number of centers | 264 | 241 | 378 |
| Disease at transplant | | | |
| AML | 16388 (35) | 7160 (37) | 3977 (33) |
| ALL | 6871 (15) | 2478 (13) | 1928 (16) |
| Other leukemia | 1469 (3) | 423 (2) | 310 (3) |
| CML | 3528 (7) | 1111 (6) | 1028 (9) |
| MDS | 6936 (15) | 3307 (17) | 1526 (13) |
| Other acute leukemia | 501 (1) | 230 (1) | 142 (1) |
| NHL | 4211 (9) | 1361 (7) | 904 (8) |
| Hodgkin Lymphoma | 947 (2) | 258 (1) | 212 (2) |
| Plasma Cell Disorders, MM | 940 (2) | 292 (2) | 206 (2) |
| Other malignancies | 58 (<1) | 14 (<1) | 22 (<1) |
| Breast cancer | 7 (<1) | 3 (<1) | 1 (<1) |
| SAA | 1519 (3) | 594 (3) | 510 (4) |
| Inherited abnormalities erythrocyte diff fxn | 728 (2) | 255 (1) | 231 (2) |
| Inherited bone marrow failure syndromes | 26 (<1) | 32 (<1) | 20 (<1) |
| Hemoglobinopathies | 22 (<1) | 22 (<1) | 15 (<1) |
| Paroxysmal nocturnal hemoglobinuria | 4 (<1) | 7 (<1) | 2 (<1) |
| SCIDs | 827 (2) | 328 (2) | 370 (3) |
| Inherited abnormalities of platelets | 40 (<1) | 16 (<1) | 12 (<1) |
| Inherited disorders of metabolism | 301 (1) | 89 (<1) | 143 (1) |
| Histiocytic disorders | 387 (1) | 125 (1) | 129 (1) |
| Autoimmune disorders | 27 (<1) | 14 (<1) | 11 (<1) |
| Other | 53 (<1) | 18 (<1) | 25 (<1) |
| MPN | 1507 (3) | 947 (5) | 297 (2) |
| Disease missing | 26 (<1) | 27 (<1) | 32 (<1) |
| AML Disease status at transplant | | | |
| CR1 | 8855 (54) | 4408 (62) | 1974 (50) |
| CR2 | 3149 (19) | 1237 (17) | 782 (20) |
| CR3+ | 337 (2) | 108 (2) | 92 (2) |
| Advanced or active disease | 3862 (24) | 1364 (19) | 984 (25) |
| Missing | 185 (1) | 43 (1) | 145 (4) |
| ALL Disease status at transplant | | | |
| CR1 | 3403 (50) | 1426 (58) | 814 (42) |
| CR2 | 1956 (28) | 631 (25) | 557 (29) |
| CR3+ | 570 (8) | 167 (7) | 180 (9) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|---|--|--|
| Advanced or active disease | 860 (13) | 230 (9) | 257 (13) |
| Missing | 82 (1) | 24 (1) | 120 (6) |
| MDS Disease status at transplant | | | |
| Early | 1480 (21) | 609 (18) | 351 (23) |
| Advanced | 4487 (65) | 2464 (75) | 836 (55) |
| Missing | 969 (14) | 234 (7) | 339 (22) |
| NHL Disease status at transplant | | | |
| CR1 | 598 (14) | 262 (19) | 125 (14) |
| CR2 | 781 (19) | 259 (19) | 145 (16) |
| CR3+ | 365 (9) | 114 (8) | 80 (9) |
| PR | 448 (11) | 112 (8) | 95 (11) |
| Advanced | 1928 (46) | 588 (43) | 424 (47) |
| Missing | 71 (2) | 18 (1) | 32 (4) |
| Recipient age at transplant | | | |
| 0-9 years | 3974 (8) | 1246 (7) | 1582 (13) |
| 10-17 years | 3152 (7) | 969 (5) | 1122 (9) |
| 18-29 years | 5720 (12) | 1928 (10) | 1607 (13) |
| 30-39 years | 5327 (11) | 1851 (10) | 1428 (12) |
| 40-49 years | 7110 (15) | 2503 (13) | 1748 (15) |
| 50-59 years | 9750 (21) | 3711 (19) | 2071 (17) |
| 60-69 years | 10023 (21) | 5257 (28) | 2052 (17) |
| 70+ years | 2267 (5) | 1646 (9) | 443 (4) |
| Median (Range) | 48 (0-84) | 53 (0-82) | 42 (0-84) |
| Recipient race/ethnicity | | | |
| White | 39105 (83) | 15871 (83) | 8419 (70) |
| Black or African American | 2150 (5) | 753 (4) | 555 (5) |
| Asian | 1167 (2) | 602 (3) | 520 (4) |
| Native Hawaiian or other Pacific Islander | 59 (<1) | 31 (<1) | 32 (<1) |
| American Indian or Alaska Native | 172 (<1) | 73 (<1) | 49 (<1) |
| Hispanic | 2873 (6) | 1076 (6) | 718 (6) |
| Missing | 1797 (4) | 705 (4) | 1760 (15) |
| Recipient sex | | | |
| Male | 27519 (58) | 11189 (59) | 7161 (59) |
| Female | 19804 (42) | 7922 (41) | 4892 (41) |
| Karnofsky score | | | |
| 10-80 | 16419 (35) | 7366 (39) | 3802 (32) |
| 90-100 | 29141 (62) | 11142 (58) | 7620 (63) |
| Missing | 1763 (4) | 603 (3) | 631 (5) |
| HLA-A B DRB1 groups - low resolution | | | |
| <=3/6 | 53 (<1) | 93 (1) | 56 (<1) |
| 4/6 | 335 (1) | 384 (2) | 359 (3) |
| 5/6 | 6476 (14) | 2365 (13) | 1782 (15) |
| 6/6 | 40016 (85) | 15559 (85) | 9621 (81) |
| Unknown | 443 (N/A) | 710 (N/A) | 235 (N/A) |
| High-resolution HLA matches available out of 8 | | | |
| <=5/8 | 1168 (2) | 1850 (10) | 1821 (17) |
| 6/8 | 1975 (4) | 591 (3) | 599 (5) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|---------------------------------------|---|--|--|
| 7/8 | 9235 (20) | 2869 (16) | 2097 (19) |
| 8/8 | 34407 (74) | 12320 (70) | 6391 (59) |
| Unknown | 538 (N/A) | 1481 (N/A) | 1145 (N/A) |
| HLA-DPB1 Match | | | |
| Double allele mismatch | 11902 (29) | 2373 (24) | 1091 (26) |
| Single allele mismatch | 22180 (54) | 5198 (52) | 2197 (52) |
| Full allele matched | 7069 (17) | 2481 (25) | 949 (22) |
| Unknown | 6172 (N/A) | 9059 (N/A) | 7816 (N/A) |
| High resolution release score | | | |
| No | 11606 (25) | 19036 (>99) | 11519 (96) |
| Yes | 35717 (75) | 75 (<1) | 534 (4) |
| KIR typing available | | | |
| No | 33478 (71) | 19085 (>99) | 11980 (99) |
| Yes | 13845 (29) | 26 (<1) | 73 (1) |
| Graft type | | | |
| Marrow | 16451 (35) | 5091 (27) | 4800 (40) |
| PBSC | 30790 (65) | 13824 (72) | 7191 (60) |
| BM+PBSC | 10 (<1) | 6 (<1) | 1 (<1) |
| PBSC+UCB | 38 (<1) | 170 (1) | 10 (<1) |
| Others | 34 (<1) | 20 (<1) | 51 (<1) |
| Conditioning regimen | | | |
| Myeloablative | 28854 (61) | 10141 (53) | 7518 (62) |
| RIC/Nonmyeloablative | 18244 (39) | 8909 (47) | 4372 (36) |
| TBD | 225 (<1) | 61 (<1) | 163 (1) |
| Donor age at donation | | | |
| To Be Determined/NA | 396 (1) | 563 (3) | 147 (1) |
| 0-9 years | 5 (<1) | 37 (<1) | 4 (<1) |
| 10-17 years | 2 (<1) | 13 (<1) | 1 (<1) |
| 18-29 years | 23149 (49) | 9900 (52) | 5152 (43) |
| 30-39 years | 13299 (28) | 4964 (26) | 3623 (30) |
| 40-49 years | 7988 (17) | 2533 (13) | 2357 (20) |
| 50+ years | 2484 (5) | 1101 (6) | 769 (6) |
| Median (Range) | 30 (0-123) | 29 (0-121) | 32 (0-123) |
| Donor/Recipient CMV serostatus | | | |
| +/+ | 11583 (24) | 4767 (25) | 3042 (25) |
| +/- | 5466 (12) | 2181 (11) | 1479 (12) |
| -/+ | 15215 (32) | 5254 (27) | 3593 (30) |
| -/- | 13359 (28) | 4498 (24) | 3132 (26) |
| CB - recipient + | 34 (<1) | 136 (1) | 9 (<1) |
| CB - recipient - | 4 (<1) | 42 (<1) | 2 (<1) |
| CB - recipient CMV unknown | 0 | 1 (<1) | 0 |
| Missing | 1662 (4) | 2232 (12) | 796 (7) |
| GvHD Prophylaxis | | | |
| No GVHD prophylaxis | 200 (<1) | 94 (<1) | 67 (1) |
| Ex vivo T-cell depletion | 1160 (2) | 319 (2) | 408 (3) |
| CD34 selection | 720 (2) | 339 (2) | 194 (2) |
| Post-CY + other(s) | 3020 (6) | 2569 (13) | 743 (6) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|--|---|---|
| Post-CY alone | 228 (<1) | 109 (1) | 58 (<1) |
| Tacrolimus + MMF +- others | 5383 (11) | 1947 (10) | 920 (8) |
| Tacrolimus + MTX +- others (except MMF) | 20389 (43) | 8407 (44) | 3390 (28) |
| Tacrolimus + others (except MTX, MMF) | 2432 (5) | 1220 (6) | 469 (4) |
| Tacrolimus alone | 1182 (2) | 484 (3) | 216 (2) |
| CSA + MMF +- others (except Tacrolimus) | 3083 (7) | 909 (5) | 1017 (8) |
| CSA + MTX +- others (except Tacrolimus, MMF) | 6993 (15) | 1899 (10) | 3358 (28) |
| CSA + others (except Tacrolimus, MTX, MMF) | 1089 (2) | 335 (2) | 452 (4) |
| CSA alone | 482 (1) | 136 (1) | 402 (3) |
| Other GVHD prophylaxis | 752 (2) | 270 (1) | 208 (2) |
| Missing | 210 (<1) | 74 (<1) | 151 (1) |
| Donor/Recipient sex match | | | |
| Male-Male | 19283 (41) | 7409 (39) | 4699 (39) |
| Male-Female | 11786 (25) | 4525 (24) | 2668 (22) |
| Female-Male | 8013 (17) | 3384 (18) | 2383 (20) |
| Female-Female | 7842 (17) | 3072 (16) | 2157 (18) |
| CB - recipient M | 18 (<1) | 96 (1) | 3 (<1) |
| CB - recipient F | 20 (<1) | 83 (<1) | 8 (<1) |
| Missing | 361 (1) | 542 (3) | 135 (1) |
| Year of transplant | | | |
| 1986-1990 | 350 (1) | 46 (<1) | 106 (1) |
| 1991-1995 | 1839 (4) | 439 (2) | 748 (6) |
| 1996-2000 | 3305 (7) | 1185 (6) | 1215 (10) |
| 2001-2005 | 5345 (11) | 1074 (6) | 1880 (16) |
| 2006-2010 | 9622 (20) | 1923 (10) | 1829 (15) |
| 2011-2015 | 13414 (28) | 3587 (19) | 2563 (21) |
| 2016-2020 | 10431 (22) | 7184 (38) | 2758 (23) |
| 2021-2022 | 3017 (6) | 3673 (19) | 954 (8) |
| Follow-up among survivors, Months | | | |
| N Eval | 20064 | 9350 | 5352 |
| Median (Range) | 60 (0-385) | 24 (0-362) | 40 (0-372) |

Unrelated Cord Blood HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|--|---|---|
| Number of patients | 6214 | 1700 | 2170 |
| Source of data | | | |
| CRF | 4494 (72) | 1137 (67) | 1068 (49) |
| TED | 1720 (28) | 563 (33) | 1102 (51) |
| Number of centers | 154 | 142 | 223 |
| Disease at transplant | | | |
| AML | 2354 (38) | 580 (34) | 706 (33) |
| ALL | 1279 (21) | 373 (22) | 468 (22) |
| Other leukemia | 98 (2) | 30 (2) | 37 (2) |
| CML | 132 (2) | 36 (2) | 57 (3) |
| MDS | 559 (9) | 168 (10) | 172 (8) |
| Other acute leukemia | 96 (2) | 24 (1) | 44 (2) |
| NHL | 403 (6) | 98 (6) | 134 (6) |
| Hodgkin Lymphoma | 103 (2) | 27 (2) | 36 (2) |
| Plasma Cell Disorders, MM | 38 (1) | 12 (1) | 13 (1) |
| Other malignancies | 11 (<1) | 1 (<1) | 3 (<1) |
| SAA | 97 (2) | 32 (2) | 49 (2) |
| Inherited abnormalities erythrocyte diff fxn | 171 (3) | 51 (3) | 45 (2) |
| Inherited bone marrow failure syndromes | 4 (<1) | 3 (<1) | 3 (<1) |
| Hemoglobinopathies | 2 (<1) | 1 (<1) | 0 |
| SCIDs | 278 (4) | 91 (5) | 165 (8) |
| Inherited abnormalities of platelets | 20 (<1) | 5 (<1) | 10 (<1) |
| Inherited disorders of metabolism | 387 (6) | 118 (7) | 142 (7) |
| Histiocytic disorders | 107 (2) | 29 (2) | 51 (2) |
| Autoimmune disorders | 9 (<1) | 0 | 6 (<1) |
| Other | 10 (<1) | 2 (<1) | 9 (<1) |
| Disease missing | 4 (<1) | 3 (<1) | 0 |
| MPN | 52 (1) | 16 (1) | 20 (1) |
| AML Disease status at transplant | | | |
| CR1 | 1222 (52) | 324 (56) | 350 (50) |
| CR2 | 636 (27) | 149 (26) | 188 (27) |
| CR3+ | 66 (3) | 9 (2) | 26 (4) |
| Advanced or active disease | 422 (18) | 96 (17) | 138 (20) |
| Missing | 8 (<1) | 2 (<1) | 4 (1) |
| ALL Disease status at transplant | | | |
| CR1 | 574 (45) | 159 (43) | 202 (43) |
| CR2 | 480 (38) | 137 (37) | 166 (35) |
| CR3+ | 148 (12) | 54 (14) | 61 (13) |
| Advanced or active disease | 76 (6) | 22 (6) | 38 (8) |
| Missing | 1 (<1) | 1 (<1) | 1 (<1) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|---|---|--|--|
| MDS Disease status at transplant | | | |
| Early | 173 (31) | 41 (24) | 72 (42) |
| Advanced | 337 (60) | 113 (67) | 78 (45) |
| Missing | 49 (9) | 14 (8) | 22 (13) |
| NHL Disease status at transplant | | | |
| CR1 | 63 (16) | 9 (9) | 25 (19) |
| CR2 | 75 (19) | 22 (22) | 35 (26) |
| CR3+ | 45 (11) | 11 (11) | 12 (9) |
| PR | 68 (17) | 12 (12) | 16 (12) |
| Advanced | 149 (37) | 43 (44) | 42 (32) |
| Missing | 0 | 1 (1) | 3 (2) |
| Recipient age at transplant | | | |
| 0-9 years | 1868 (30) | 612 (36) | 771 (36) |
| 10-19 years | 655 (11) | 158 (9) | 255 (12) |
| 20-29 years | 745 (12) | 152 (9) | 234 (11) |
| 30-39 years | 599 (10) | 150 (9) | 210 (10) |
| 40-49 years | 655 (11) | 172 (10) | 203 (9) |
| 50-59 years | 856 (14) | 210 (12) | 280 (13) |
| 60-69 years | 722 (12) | 212 (12) | 201 (9) |
| 70+ years | 114 (2) | 34 (2) | 16 (1) |
| Median (Range) | 27 (0-83) | 24 (0-78) | 20 (0-78) |
| Recipient race/ethnicity | | | |
| White | 3432 (55) | 996 (59) | 1090 (50) |
| Black or African American | 893 (14) | 221 (13) | 263 (12) |
| Asian | 366 (6) | 120 (7) | 163 (8) |
| Native Hawaiian or other Pacific Islander | 32 (1) | 3 (<1) | 17 (1) |
| American Indian or Alaska Native | 45 (1) | 10 (1) | 19 (1) |
| Hispanic | 1108 (18) | 253 (15) | 297 (14) |
| Missing | 338 (5) | 97 (6) | 321 (15) |
| Recipient sex | | | |
| Male | 3439 (55) | 968 (57) | 1241 (57) |
| Female | 2775 (45) | 732 (43) | 929 (43) |
| Karnofsky score | | | |
| 10-80 | 1647 (27) | 437 (26) | 556 (26) |
| 90-100 | 4361 (70) | 1157 (68) | 1433 (66) |
| Missing | 206 (3) | 106 (6) | 181 (8) |
| HLA-A B DRB1 groups - low resolution | | | |
| <=3/6 | 118 (2) | 65 (4) | 44 (2) |
| 4/6 | 2485 (41) | 657 (41) | 839 (40) |
| 5/6 | 2707 (45) | 677 (42) | 915 (44) |
| 6/6 | 771 (13) | 219 (14) | 299 (14) |
| Unknown | 133 (N/A) | 82 (N/A) | 73 (N/A) |
| High-resolution HLA matches available out of 8 | | | |
| <=5/8 | 3372 (57) | 750 (54) | 1169 (58) |
| 6/8 | 1387 (23) | 345 (25) | 449 (22) |
| 7/8 | 789 (13) | 191 (14) | 260 (13) |
| 8/8 | 380 (6) | 96 (7) | 136 (7) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--------------------------------|---|--|--|
| Unknown | 286 (N/A) | 318 (N/A) | 156 (N/A) |
| HLA-DPB1 Match | | | |
| Double allele mismatch | 888 (38) | 148 (37) | 194 (39) |
| Single allele mismatch | 1224 (53) | 213 (53) | 262 (52) |
| Full allele matched | 214 (9) | 40 (10) | 47 (9) |
| Unknown | 3888 (N/A) | 1299 (N/A) | 1667 (N/A) |
| High resolution release score | | | |
| No | 4674 (75) | 1650 (97) | 2145 (99) |
| Yes | 1540 (25) | 50 (3) | 25 (1) |
| KIR typing available | | | |
| No | 4941 (80) | 1694 (>99) | 2150 (99) |
| Yes | 1273 (20) | 6 (<1) | 20 (1) |
| Graft type | | | |
| UCB | 5836 (94) | 1521 (89) | 2034 (94) |
| BM+UCB | 1 (<1) | 0 | 0 |
| PBSC+UCB | 347 (6) | 170 (10) | 122 (6) |
| Others | 30 (<1) | 9 (1) | 14 (1) |
| Number of cord units | | | |
| 1 | 5200 (84) | 0 | 1809 (83) |
| 2 | 1012 (16) | 0 | 360 (17) |
| 3 | 1 (<1) | 0 | 0 |
| Unknown | 1 (N/A) | 1700 (N/A) | 1 (N/A) |
| Conditioning regimen | | | |
| Myeloablative | 4030 (65) | 1076 (63) | 1346 (62) |
| RIC/Nonmyeloablative | 2168 (35) | 619 (36) | 807 (37) |
| TBD | 16 (<1) | 5 (<1) | 17 (1) |
| Donor age at donation | | | |
| To Be Determined/NA | 4858 (78) | 646 (38) | 1741 (80) |
| 0-9 years | 1081 (17) | 844 (50) | 348 (16) |
| 10-17 years | 58 (1) | 88 (5) | 17 (1) |
| 18-29 years | 65 (1) | 37 (2) | 15 (1) |
| 30-39 years | 57 (1) | 38 (2) | 21 (1) |
| 40-49 years | 46 (1) | 21 (1) | 11 (1) |
| 50+ years | 49 (1) | 26 (2) | 17 (1) |
| Median (Range) | 4 (0-112) | 5 (0-73) | 4 (0-119) |
| Donor/Recipient CMV serostatus | | | |
| +/+ | 0 | 0 | 1 (<1) |
| -/- | 0 | 0 | 1 (<1) |
| CB - recipient + | 3888 (63) | 1027 (60) | 1306 (60) |
| CB - recipient - | 2227 (36) | 613 (36) | 790 (36) |
| CB - recipient CMV unknown | 99 (2) | 60 (4) | 72 (3) |
| GvHD Prophylaxis | | | |
| No GVHD prophylaxis | 23 (<1) | 8 (<1) | 14 (1) |
| Ex vivo T-cell depletion | 25 (<1) | 9 (1) | 8 (<1) |
| CD34 selection | 213 (3) | 100 (6) | 61 (3) |
| Post-CY + other(s) | 12 (<1) | 9 (1) | 13 (1) |
| Post-CY alone | 0 | 0 | 1 (<1) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|---|--|---|---|
| Tacrolimus + MMF +/- others | 1857 (30) | 539 (32) | 446 (21) |
| Tacrolimus + MTX +/- others (except MMF) | 216 (3) | 56 (3) | 78 (4) |
| Tacrolimus + others (except MTX, MMF) | 225 (4) | 64 (4) | 84 (4) |
| Tacrolimus alone | 153 (2) | 45 (3) | 30 (1) |
| CSA + MMF +/- others (except Tacrolimus) | 2847 (46) | 683 (40) | 1039 (48) |
| CSA + MTX +/- others (except Tacrolimus, MMF) | 101 (2) | 29 (2) | 50 (2) |
| CSA + others (except Tacrolimus, MTX, MMF) | 341 (5) | 117 (7) | 223 (10) |
| CSA alone | 52 (1) | 18 (1) | 70 (3) |
| Other GVHD prophylaxis | 137 (2) | 20 (1) | 42 (2) |
| Missing | 12 (<1) | 3 (<1) | 11 (1) |
| Donor/Recipient sex match | | | |
| Male-Female | 0 | 0 | 1 (<1) |
| Female-Male | 0 | 0 | 1 (<1) |
| CB - recipient M | 3439 (55) | 968 (57) | 1239 (57) |
| CB - recipient F | 2775 (45) | 732 (43) | 928 (43) |
| CB - recipient sex unknown | 0 | 0 | 1 (<1) |
| Year of transplant | | | |
| 1996-2000 | 1 (<1) | 2 (<1) | 5 (<1) |
| 2001-2005 | 112 (2) | 86 (5) | 34 (2) |
| 2006-2010 | 1850 (30) | 426 (25) | 601 (28) |
| 2011-2015 | 2682 (43) | 510 (30) | 839 (39) |
| 2016-2020 | 1341 (22) | 528 (31) | 547 (25) |
| 2021-2022 | 228 (4) | 148 (9) | 144 (7) |
| Follow-up among survivors, Months | | | |
| N Eval | 2964 | 887 | 1105 |
| Median (Range) | 64 (0-196) | 49 (0-213) | 43 (0-240) |

Related Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|---|--|--|
| Number of patients | 11071 | 1859 | 851 |
| Source of data | | | |
| CRF | 3500 (32) | 454 (24) | 281 (33) |
| TED | 7571 (68) | 1405 (76) | 570 (67) |
| Number of centers | 93 | 78 | 63 |
| Disease at transplant | | | |
| AML | 3667 (33) | 605 (33) | 285 (33) |
| ALL | 1843 (17) | 362 (19) | 163 (19) |
| Other leukemia | 205 (2) | 41 (2) | 19 (2) |
| CML | 337 (3) | 45 (2) | 24 (3) |
| MDS | 1483 (13) | 226 (12) | 111 (13) |
| Other acute leukemia | 164 (1) | 33 (2) | 11 (1) |
| NHL | 936 (8) | 168 (9) | 76 (9) |
| Hodgkin Lymphoma | 204 (2) | 40 (2) | 23 (3) |
| Plasma Cell Disorders, MM | 257 (2) | 39 (2) | 23 (3) |
| Other malignancies | 24 (<1) | 0 | 1 (<1) |
| Breast cancer | 1 (<1) | 0 | 0 |
| SAA | 516 (5) | 81 (4) | 29 (3) |
| Inherited abnormalities erythrocyte diff fxn | 494 (4) | 72 (4) | 20 (2) |
| Inherited bone marrow failure syndromes | 16 (<1) | 2 (<1) | 4 (<1) |
| Hemoglobinopathies | 111 (1) | 22 (1) | 8 (1) |
| Paroxysmal nocturnal hemoglobinuria | 2 (<1) | 0 | 0 |
| SCIDs | 228 (2) | 36 (2) | 16 (2) |
| Inherited abnormalities of platelets | 10 (<1) | 0 | 0 |
| Inherited disorders of metabolism | 16 (<1) | 5 (<1) | 2 (<1) |
| Histiocytic disorders | 63 (1) | 9 (<1) | 5 (1) |
| Autoimmune disorders | 11 (<1) | 0 | 1 (<1) |
| Other | 16 (<1) | 0 | 0 |
| Disease missing | 10 (<1) | 4 (<1) | 1 (<1) |
| MPN | 457 (4) | 69 (4) | 29 (3) |
| AML Disease status at transplant | | | |
| CR1 | 2403 (66) | 411 (68) | 186 (65) |
| CR2 | 562 (15) | 86 (14) | 36 (13) |
| CR3+ | 44 (1) | 14 (2) | 1 (<1) |
| Advanced or active disease | 651 (18) | 90 (15) | 62 (22) |
| Missing | 7 (<1) | 4 (1) | 0 |
| ALL Disease status at transplant | | | |
| CR1 | 1119 (61) | 226 (62) | 103 (63) |
| CR2 | 522 (28) | 91 (25) | 40 (25) |
| CR3+ | 114 (6) | 19 (5) | 11 (7) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|--|---|--|--|
| Advanced or active disease | 86 (5) | 26 (7) | 9 (6) |
| Missing | 2 (<1) | 0 | 0 |
| MDS Disease status at transplant | | | |
| Early | 253 (17) | 31 (14) | 20 (18) |
| Advanced | 1177 (79) | 183 (81) | 85 (77) |
| Missing | 53 (4) | 12 (5) | 6 (5) |
| NHL Disease status at transplant | | | |
| CR1 | 174 (19) | 39 (23) | 16 (21) |
| CR2 | 176 (19) | 34 (20) | 10 (13) |
| CR3+ | 100 (11) | 18 (11) | 4 (5) |
| PR | 68 (7) | 13 (8) | 7 (9) |
| Advanced | 409 (44) | 63 (38) | 39 (51) |
| Missing | 5 (1) | 0 | 0 |
| Recipient age at transplant | | | |
| 0-9 years | 1123 (10) | 180 (10) | 68 (8) |
| 10-19 years | 1071 (10) | 139 (7) | 63 (7) |
| 20-29 years | 1257 (11) | 250 (13) | 90 (11) |
| 30-39 years | 865 (8) | 166 (9) | 88 (10) |
| 40-49 years | 1356 (12) | 218 (12) | 99 (12) |
| 50-59 years | 2336 (21) | 401 (22) | 185 (22) |
| 60-69 years | 2583 (23) | 431 (23) | 226 (27) |
| 70+ years | 480 (4) | 74 (4) | 32 (4) |
| Median (Range) | 49 (0-82) | 49 (0-76) | 51 (0-83) |
| Recipient race/ethnicity | | | |
| White | 6869 (62) | 977 (53) | 514 (60) |
| Black or African American | 1373 (12) | 240 (13) | 81 (10) |
| Asian | 518 (5) | 138 (7) | 43 (5) |
| Native Hawaiian or other Pacific Islander | 34 (<1) | 5 (<1) | 2 (<1) |
| American Indian or Alaska Native | 47 (<1) | 4 (<1) | 4 (<1) |
| Hispanic | 1677 (15) | 357 (19) | 151 (18) |
| Missing | 553 (5) | 138 (7) | 56 (7) |
| Recipient sex | | | |
| Male | 6513 (59) | 1084 (58) | 496 (58) |
| Female | 4558 (41) | 775 (42) | 355 (42) |
| Karnofsky score | | | |
| 10-80 | 3971 (36) | 745 (40) | 349 (41) |
| 90-100 | 6760 (61) | 1052 (57) | 454 (53) |
| Missing | 340 (3) | 62 (3) | 48 (6) |
| HLA-A B DRB1 groups - low resolution | | | |
| <=3/6 | 2391 (23) | 382 (23) | 190 (27) |
| 4/6 | 735 (7) | 137 (8) | 86 (12) |
| 5/6 | 252 (2) | 52 (3) | 27 (4) |
| 6/6 | 7083 (68) | 1120 (66) | 410 (58) |
| Unknown | 610 (N/A) | 168 (N/A) | 138 (N/A) |
| High-resolution HLA matches available out of 8 | | | |
| <=5/8 | 3078 (30) | 502 (31) | 248 (37) |
| 6/8 | 150 (1) | 39 (2) | 18 (3) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|---------------------------------------|---|--|--|
| 7/8 | 200 (2) | 41 (3) | 29 (4) |
| 8/8 | 6828 (67) | 1041 (64) | 367 (55) |
| Unknown | 815 (N/A) | 236 (N/A) | 189 (N/A) |
| HLA-DPB1 Match | | | |
| Double allele mismatch | 21 (<1) | 6 (1) | 4 (1) |
| Single allele mismatch | 2510 (28) | 257 (28) | 136 (36) |
| Full allele matched | 6416 (72) | 660 (72) | 234 (63) |
| Unknown | 2124 (N/A) | 936 (N/A) | 477 (N/A) |
| High resolution release score | | | |
| No | 4655 (42) | 1830 (98) | 835 (98) |
| Yes | 6416 (58) | 29 (2) | 16 (2) |
| Graft type | | | |
| Marrow | 3187 (29) | 431 (23) | 238 (28) |
| PBSC | 7789 (70) | 1395 (75) | 599 (70) |
| UCB | 2 (<1) | 14 (1) | 0 |
| BM+PBSC | 8 (<1) | 4 (<1) | 1 (<1) |
| BM+UCB | 30 (<1) | 9 (<1) | 2 (<1) |
| PBSC+UCB | 0 | 0 | 11 (1) |
| Others | 55 (<1) | 6 (<1) | 0 |
| Conditioning regimen | | | |
| Myeloablative | 6168 (56) | 1021 (55) | 439 (52) |
| RIC/Nonmyeloablative | 4849 (44) | 825 (44) | 395 (46) |
| TBD | 54 (<1) | 13 (1) | 17 (2) |
| Donor age at donation | | | |
| To Be Determined/NA | 15 (<1) | 3 (<1) | 8 (1) |
| 0-9 years | 761 (7) | 119 (6) | 32 (4) |
| 10-17 years | 843 (8) | 139 (7) | 52 (6) |
| 18-29 years | 1915 (17) | 319 (17) | 167 (20) |
| 30-39 years | 1633 (15) | 323 (17) | 161 (19) |
| 40-49 years | 1796 (16) | 300 (16) | 115 (14) |
| 50+ years | 4108 (37) | 656 (35) | 316 (37) |
| Median (Range) | 42 (0-122) | 41 (0-118) | 41 (0-121) |
| Donor/Recipient CMV serostatus | | | |
| +/+ | 4485 (41) | 812 (44) | 288 (34) |
| +/- | 1187 (11) | 151 (8) | 72 (8) |
| -/+ | 2766 (25) | 443 (24) | 198 (23) |
| -/- | 2371 (21) | 381 (20) | 162 (19) |
| CB - recipient + | 24 (<1) | 14 (1) | 7 (1) |
| CB - recipient - | 8 (<1) | 9 (<1) | 6 (1) |
| Missing | 230 (2) | 49 (3) | 118 (14) |
| GvHD Prophylaxis | | | |
| No GVHD prophylaxis | 156 (1) | 35 (2) | 16 (2) |
| Ex vivo T-cell depletion | 114 (1) | 31 (2) | 11 (1) |
| CD34 selection | 119 (1) | 33 (2) | 13 (2) |
| Post-CY + other(s) | 3488 (32) | 547 (29) | 309 (36) |
| Post-CY alone | 76 (1) | 11 (1) | 8 (1) |
| Tacrolimus + MMF +/- others | 794 (7) | 93 (5) | 26 (3) |

Refresh date: Dec 2022

| Variable | Samples Available for Recipient and Donor N (%) | Samples Available for Recipient Only N (%) | Samples Available for Donor Only N (%) |
|---|--|---|---|
| Tacrolimus + MTX +/- others (except MMF) | 4050 (37) | 606 (33) | 309 (36) |
| Tacrolimus + others (except MTX, MMF) | 815 (7) | 292 (16) | 67 (8) |
| Tacrolimus alone | 108 (1) | 22 (1) | 7 (1) |
| CSA + MMF +/- others (except Tacrolimus) | 243 (2) | 38 (2) | 15 (2) |
| CSA + MTX +/- others (except Tacrolimus, MMF) | 719 (6) | 95 (5) | 43 (5) |
| CSA + others (except Tacrolimus, MTX, MMF) | 81 (1) | 11 (1) | 3 (<1) |
| CSA alone | 85 (1) | 12 (1) | 4 (<1) |
| Other GVHD prophylaxis | 148 (1) | 19 (1) | 15 (2) |
| Missing | 75 (1) | 14 (1) | 5 (1) |
| Donor/Recipient sex match | | | |
| Male-Male | 3666 (33) | 646 (35) | 285 (33) |
| Male-Female | 2322 (21) | 388 (21) | 182 (21) |
| Female-Male | 2791 (25) | 415 (22) | 196 (23) |
| Female-Female | 2200 (20) | 374 (20) | 164 (19) |
| CB - recipient M | 21 (<1) | 16 (1) | 8 (1) |
| CB - recipient F | 11 (<1) | 7 (<1) | 5 (1) |
| Missing | 60 (1) | 13 (1) | 11 (1) |
| Year of transplant | | | |
| 2006-2010 | 601 (5) | 71 (4) | 61 (7) |
| 2011-2015 | 3701 (33) | 503 (27) | 203 (24) |
| 2016-2020 | 5028 (45) | 894 (48) | 399 (47) |
| 2021-2022 | 1741 (16) | 391 (21) | 188 (22) |
| Follow-up among survivors, Months | | | |
| N Eval | 6629 | 1113 | 510 |
| Median (Range) | 35 (0-150) | 24 (0-124) | 24 (0-148) |